Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity. by Nakamura, MC et al.
UCSF
UC San Francisco Previously Published Works
Title
Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity.
Permalink
https://escholarship.org/uc/item/0398g12f
Journal
The Journal of experimental medicine, 189(3)
ISSN
0022-1007
Authors
Nakamura, MC
Linnemeyer, PA
Niemi, EC
et al.
Publication Date
1999-02-01
DOI
10.1084/jem.189.3.493
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
 493
 
The Journal of Experimental Medicine • Volume 189, Number 3, February 1, 1999 493–500
http://www.jem.org
 
Mouse Ly-49D Recognizes H-2D
 
d
 
 and Activates Natural 
Killer Cell Cytotoxicity
 
By Mary C. Nakamura,
 
*
 
 Paul A. Linnemeyer,
 
*
 
 Eréne C. Niemi,
 
*
 
 
Llewellyn H. Mason,
 
‡
 
 John R. Ortaldo,
 
‡
 
 James C. Ryan,
 
*
 
and William E. Seaman
 
*
 
§
 
From the 
 
*
 
Department of Medicine, University of California San Francisco, San Francisco, California 
94143, and the Veterans Administration Medical Center, San Francisco, California 94121; the 
 
‡
 
Laboratory of Experimental Immunology, National Cancer Institute–Frederick Cancer Research and 
Development Center, Frederick, Maryland 21702; and the 
 
§
 
Department of Microbiology and 
Immunology, University of California San Francisco, San Francisco, California 94143
 
Summary
 
Although activation of natural killer (NK) cytotoxicity is generally inhibited by target major
histocompatibility complex (MHC) class I expression, subtle features of NK allorecognition
suggest that NK cells possess receptors that are activated by target MHC I. The mouse Ly-49D
receptor has been shown to activate NK cytotoxicity, although recognition of MHC class I has
not been demonstrated previously. To define Ly-49D–ligand interactions, we transfected the
mouse Ly-49D receptor into the rat NK line, RNK-16 (RNK.mLy-49D). As expected, anti–
Ly-49D monoclonal antibody 12A8 specifically stimulated redirected lysis of the Fc receptor–
bearing rat target YB2/0 by RNK.mLy-49D transfectants. RNK.mLy-49D effectors were
tested against YB2/0 targets transfected with the mouse MHC I alleles H-2D
 
d
 
, D
 
b
 
, K
 
k
 
, or K
 
b
 
.
RNK.mLy-49D cells lysed YB2/0.D
 
d
 
 targets more efficiently than untransfected YB2/0 or
YB2/0 transfected with D
 
b
 
, K
 
k
 
, or K
 
b
 
. This augmented lysis of H-2D
 
d
 
 targets was specifically
inhibited by F(ab
 
9
 
)
 
2
 
 anti–Ly-49D (12A8) and F(ab
 
9
 
)
 
2
 
 anti–H-2D
 
d
 
 (34-5-8S). RNK.mLy-49D
effectors were also able to specifically lyse Concanavalin A blasts isolated from H-2
 
d
 
 mice
(BALB/c, B10.D2, and DBA/2) but not from H-2
 
b
 
 or H-2
 
k
 
 mice. These experiments show
that the activating receptor Ly-49D specifically interacts with the MHC I antigen, H-2D
 
d
 
,
demonstrating the existence of alloactivating receptors on murine NK cells.
Key words: natural killer cells • major histocompatibility complex • receptors • cytotoxicity • 
rodent
 
N
 
atural killer (NK) lymphocytes have the ability to rec-
ognize and to lyse various targets, including neoplastic
and hematopoietic cells, although the specific activating re-
ceptors involved remain poorly characterized (1–4). In
contrast to allogeneic killing by CD8
 
1
 
 T lymphocytes, NK
cytotoxicity is generally inhibited, rather than activated, by
the expression of class I MHC antigens on targets (5). Inhi-
bition of natural killing is mediated by polymorphic inhibi-
tory NK cell receptors, which are specific for distinct
MHC class I alleles (6–8). Each of the known MHC-bind-
ing inhibitory NK cell receptors is a member of a family of
molecules (killer cell inhibitory receptor [KIR], Ly-49, or
CD94/NKG2) with related sequences (8–12). Within each
family, receptors that mediate inhibitory function all con-
tain a cytoplasmic immunoreceptor tyrosine based inhibi-
tory motif (ITIM).
 
1
 
 However, each family also includes re-
lated receptors that lack ITIMs (4, 8, 13), and recent studies
have shown that some of these receptors can activate NK
cells (14, 15).
Although the target ligands for these stimulatory recep-
tors have not yet been defined, their extracellular domains
share homology with the corresponding domains of MHC-
binding inhibitory receptors, suggesting that activating re-
ceptors may also bind MHC class I antigens (4, 8, 16–18).
Consistent with this hypothesis, functional studies in mice
and rats suggest that NK cells, like T cells, may express re-
ceptors that activate cytotoxicity in response to MHC class
I ligands (19–22).
 
The first two authors contributed equally to this work.
 
1
 
Abbreviation used in this paper:
 
 ITIM, immunoreceptor tyrosine based in-
hibitory motif.
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Activation of the Ly-49D Receptor by H-2D
 
d
 
We have studied the mouse Ly-49D receptor, which
was shown by Mason et al. to activate NK cells (14). Initial
attempts to define the ligand specificity of Ly-49D in vitro
were unsuccessful, although in vivo studies have implicated
Ly-49D
 
1
 
 NK cells in the clearance of allogeneic targets
(14, 23). It is likely that attempts to define MHC ligands
for Ly-49D using Ly-49D–enriched primary mouse NK
cells have been complicated by the coexpression of inhibi-
tory MHC-binding NK receptors (14). To define the spec-
ificity of mouse Ly-49D, we transfected the Ly-49D recep-
tor into the rat NK cell tumor line, RNK-16, which
expresses none of the known mouse inhibitory allorecep-
tors. We examined the cytotoxicity of RNK.mLy-49D
transfectants against a panel of targets expressing polymor-
phic alleles of murine MHC class I. We demonstrate here
that Ly-49D specifically stimulates cytotoxicity of targets
expressing H-2D
 
d
 
, but not of targets expressing H-2
 
b
 
 or
H-2
 
k
 
 MHC antigens. This H-2D
 
d
 
–augmented killing can
be blocked by F(ab
 
9
 
)
 
2
 
 anti–Ly-49D or F(ab
 
9
 
)
 
2
 
 anti–H-2D
 
d
 
.
These experiments identify Ly-49D as an activating recep-
tor for mouse H-2D
 
d
 
, and therefore demonstrate the exist-
ence of alloactivating receptors on murine NK cells.
 
Materials and Methods
 
Cells.
 
RNK-16, a spontaneous NK cell leukemia from F344
rats, was a gift from Craig Reynolds (NCI, Frederick, MD) and
was adapted for in vitro growth in cRPMI (RPMI 1640 supple-
mented with 10% heat-inactivated FCS, 25 
 
m
 
M 2-ME, 2 mM
 
l
 
-glutamine, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin)
(24). Tumor target cell lines cultured in cRPMI included YAC-1
(mouse lymphoma, H-2
 
a
 
) and YB2/0 (rat myeloma) from the
American Type Culture Collection. The mouse Ly-49A trans-
fectant of RNK-16, RNK.mLy-49A (previously described as
RNK-mLy-49A.9; reference 25), was grown in cRPMI supple-
mented with 1 mg/ml of G418 (Boehringer Mannheim). Trans-
fected RNK-16 effectors and transfected YB2/0 targets were
maintained in 1 mg/ml G418, but were grown in cRPMI with-
out G418 for at least 2 d before functional assays.
 
Antibodies and Flow Cytometry.
 
mAbs to mouse Ly-49D (12A8,
rat IgG2a), OVA (2C7, rat IgG2a), or H-2D
 
d
 
 (34-5-8S, mouse
IgG2a) were produced from their respective hybridoma lines.
Antibodies were partially purified from ascites by ammonium
sulfate precipitation. F(ab
 
9
 
)
 
2
 
 fragments were generated by pepsin
digestion (26), and completion of digestion was verified by SDS-
PAGE and silver staining. For fluorescence analysis, mAbs were
used at a concentration of 1 
 
m
 
g/10
 
6
 
 cells. Routine analysis was
performed using a FACScan
 
®
 
.
 
Cytotoxicity Assays.
 
Specific lysis of NK targets was deter-
mined by using a standard 4-h 
 
51
 
Cr-release assay as previously de-
scribed (27). In brief, target cells were harvested and labeled for 1 h
at 37
 
8
 
C with 200 
 
m
 
Ci of [
 
51
 
Cr]sodium chromate (Amersham) in
complete RPMI. Labeled target cells were washed and resus-
pended at 10
 
5
 
 cells/ml, and 0.1 ml of this cell suspension was
added to each well of 96-well plates containing 0.1 ml of effector
cells at the indicated E/T ratios. Plates were incubated at 37
 
8
 
C
for 4 h, then centrifuged for 5 min. 100 
 
m
 
l of supernatant was
counted in a gamma counter and the specific cytoxicity was cal-
culated as previously described (27). All assays were performed in
triplicate. For antibody inhibition studies, effector cells were pre-
incubated for 15 min at room temperature with F(ab
 
9
 
)
 
2
 
 at a con-
 
centration of 25 
 
m
 
g/10
 
6
 
 effectors or with intact antibody at a
concentration of 10 
 
m
 
g/10
 
6
 
 effectors before the addition of targets.
 
Vectors and cDNA.
 
The Ly-49D cDNA was obtained by PCR
amplification from cDNA prepared from 7-d–IL-2-activated
LAK cells from C57BL/6J mice using the 5
 
9
 
 primer 5
 
9
 
-TCACA-
GAAATCACTCAAGGACAT-3
 
9
 
 and the 3
 
9
 
 primer 5
 
9
 
-TTT-
ACTTTTAACACTCAC-3
 
9
 
. The Ly-49D cDNA obtained is
identical to the Ly-49D cDNA previously published in the extracel-
lular and transmembrane domains (17). There is a 9-nucleotide in-
sertion at the 3
 
9
 
 end of the coding sequence for the cytoplasmic do-
main in the Ly-49D cDNA obtained and used in these studies,
which is identical to the alternately spliced long Ly-49D cDNA se-
quence published by Silver et al. (28). The protein sequence of the
44-amino acid cytoplasmic domain of the Ly-49D cDNA obtained
reads MTEQEDTFSAVRFHKSSGLQNEMRLKETRKPEKA-
RLRVCSVPWQ (the initial published sequence is identical except
it lacks the underlined 3-amino acid insertion). This Ly-49D cDNA
PCR product was subcloned into the TA cloning vector, pCR2.1
Figure 1. The mouse Ly-49D receptor, expressed on RNK-16 cells, me-
diates redirected lysis of the FcR-bearing target YB2/0 in the presence of
anti–Ly-49D mAb. Staining for Ly-49D on wild-type RNK-16 cells (A)
and RNK.mLy-49D transfectants (B) is shown by FACS® analysis of cells
exposed to anti–Ly-49D mAb 12A8 (filled histogram) and FITC-conjugated
goat anti–rat antibody (FITC-GAR) or FITC-GAR alone (dotted line).
Standard 4-h cytotoxicity assays were performed with either FcR-bearing
rat myeloma YB2/0 cells or YAC-1 cells as targets. RNK-16 effectors are
shown on the left in C, E, and G, and RNK.mLy-49D effectors are shown
on the right in D, F, and H. To measure redirected lysis by the Ly-49D re-
ceptor, effectors in C and D were preincubated with either media alone (h),
intact anti–Ly-49D mAb (12A8) (r), or intact isotype-matched control
mAb (2C7) (s), before addition of YB2/0 targets. In E and F, effectors
were preincubated with media alone (h), anti–Ly-49D F(ab9)2 fragments
(m), or control F(ab9)2 fragments (s). G and H show lysis of YAC-1 targets.
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(Invitrogen), shuttled through the vector pSP72 (Promega) using the
5
 
9
 
 Hind III/XbaI 3
 
9
 
 sites, and then ligated into the XhoI site in the
expression vector BSR
 
a
 
EN
 
 (a gift from A. Shaw and M. Olszowy,
Washington University, St. Louis, MO). Constructs were confirmed
by sequencing in both directions before transfection. Vectors used to
transfect YB2/0 target cells with H-2D
 
d
 
, H-2D
 
b
 
, and chimeric
H-2D
 
d/b
 
 class I MHC have been described previously (29). The chi-
meric molecules were made by exon shuffling between genomic
clones of H-2D
 
d
 
 and H-2D
 
b
 
 using standard methods (30), and details
of the construction have been described previously (29). The chi-
meric molecule that we have termed D
 
d
 
a
 
1
 
a
 
2
 
D
 
b
 
 
 
encodes the 
 
a
 
1
 
 and
 
a
 
2
 
 domains of H-2D
 
d
 
 with the 
 
a
 
3
 
 domain of H-2D
 
b
 
. The chimeric
molecule that we have termed D
 
b
 
a
 
1
 
a
 
2
 
D
 
d
 
 encodes the 
 
a
 
1
 
 and 
 
a
 
2
 
 do-
mains of H-2D
 
b
 
 with the 
 
a
 
3
 
 domain of H-2D
 
d
 
.
 
Transfections. YB2/0 or RNK-16 cells were transfected by
electroporation as previously described, using cesium-purified ge-
nomic plasmids or Qiagen-purified (Qiagen) cDNA plasmids us-
ing standard methods (25, 29).
Mice. Strain C57BL/6, BALB/c, BALB.B10 (C.B10-H-2b/
LiMcdJ), BALB.K (C.B10-H-2k/LiMcdJ), B10.D2, B10.BR,
B10.S, DBA/2, and C3H mice were obtained from The Jackson
Laboratory and were used at 6–8 wk of age.
Con A Blast Preparation. Con A–stimulated blasts were prepared
from the spleens of mice from the strains described above, using
methods that have been described previously (31). In brief, spleens
were harvested aseptically and separated into single cell suspensions.
After lysis of red blood cells, cells were washed in cRPMI and
placed in culture at a density of 106 cells/ml in cRPMI with 3 mg/
ml Con A (Sigma Chemical Co.). After 48 h of culture at 378C,
cells were harvested, purified over Ficoll-Hypaque, washed twice in
cRPMI, and labeled for use as targets in cytotoxicity assays.
Results
Mouse Ly-49D Functions as an Activating Receptor in RNK-
16 Cells. To examine Ly-49D–ligand interactions in the
absence of mouse inhibitory NK cell receptors, we trans-
fected the mouse Ly-49D receptor into RNK-16, a rat tu-
mor cell line with phenotypic and functional characteristics
of rat NK cells (24). Cell-surface staining of a representa-
tive RNK.mLy-49D clone with the anti–Ly-49D mAb,
12A8, is shown in Fig. 1 B. In murine NK cells, the Ly-
49D receptor has previously been demonstrated to mediate
“redirected lysis” of FcR-bearing targets in the presence of
the anti–Ly-49D mAb, 12A8 (14). As shown in Fig. 1 D,
killing of the FcR-bearing target YB2/0 by the RNK.
mLy-49D transfectant was similarly stimulated by anti–Ly-
49D mAb, but not by isotype-matched control mAb. Nei-
ther F(ab9)2 anti–Ly-49D nor control F(ab9)2 2C7 had any
effect on cytotoxicity (panel F), indicating that the binding
of the intact mAb to target FcR is required for augmenta-
tion of killing of YB2/0 (redirected lysis). Lysis of YB2/0
by wild-type RNK-16 cells was unchanged by mAb anti–
Ly-49D, by control mAb (panel E), or by F(ab9)2 fragments
derived from either antibody (panel G). These studies dem-
onstrate that the mouse Ly-49D receptor can function as an
activating receptor in RNK-16.
RNK.mLy-49D transfectants were also tested against the
standard NK cell tumor target, YAC-1. Interestingly, kill-
ing of YAC-1 by RNK.mLy-49D was decreased compared
with killing by RNK-16 (Fig. 1, G and H). The anti–Ly-
49D mAb, 12A8, had no effect on the lysis of YAC-1 by
RNK.mLy-49D transfectants (data not shown).
Mouse Ly-49D Is Activated by H-2Dd on YB2/0 Targets.
To examine the MHC restriction of Ly-49D, we tested the
RNK.mLy-49D transfectant in cytotoxicity assays against a
panel of rat YB2/0 myeloma target cells transfected with
one of the murine H-2 alleles Dd, Db, Kb, or Kk. As seen in
Fig. 2, RNK-mLy-49D effectors lysed YB2/0.Dd targets
Figure 2. The Ly-49D receptor
activates lysis of H-2Dd–express-
ing YB2/0 target cells. Standard
4-h cytotoxicity assays were
performed using either RNK.
mLy-49D transfectants (A–D),
wild-type RNK-16 (E–H), or
RNK.mLy-49A transfectants
(I–L) as effectors. Each effector
was tested against a panel of
YB2/0 cells transfected with one
of the MHC class I alleles as tar-
gets: panels A, E, and I, H-2Dd;
panels B, F, and J, Db; panels C,
G, and K, Kb; panels D, H, and
L, Kk. Effector cells were prein-
cubated with media alone (h),
anti–Ly-49D (12A8) F(ab9)2
fragments (r), or control (2C7)
F(ab9)2 fragments (s).
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(panel A) more efficiently than YB2/0.Db (panel B), YB2/
0.Kb (panel C), or YB2/0.Kk (panel D). Augmented killing
of YB2/0.Dd by RNK.mLy-49D effectors was specifically
blocked by F(ab9)2 anti–Ly-49D (12A8), but not by iso-
type-matched control F(ab9)2 2C7 (panel A). Lysis of the
YB2/0.Dd, Db, Kb, and Kk transfectants by wild-type
RNK-16 was unchanged in the presence of F(ab9)2 anti–
Ly-49D or control F(ab9)2 2C7 (panels E–H). We previ-
ously described RNK-16 cells transfected with the mouse
NK inhibitory receptor, Ly-49A (RNK.mLy-49A), which
also recognizes H-2Dd (25). In contrast to RNK.mLy-49D
cells, which were activated by YB2/0.Dd cells, RNK.mLy-
49A cells were unable to lyse YB2/0.Dd cells, as they were
inhibited through the Ly-49A receptor. Because the 12A8
mAb binds to Ly-49A as well as to Ly-49D (14), we were
able examine the effects of 12A8 on lysis by RNK.mLy-49A
cells. As shown in Fig. 2 A, F(ab9)2 12A8 blocked H-2Dd–
specific activation of cytotoxicity by RNK.mLy-49D cells,
but reversed H-2Dd–specific inhibition of lysis by RNK.
mLy-49A cells (panel I). Thus, the activating Ly-49D recep-
tor and the inhibitory Ly-49A receptor share ligand specific-
ity for H-2Dd on target cells, and the interaction between
ligand H-2Dd and either Ly-49A or Ly-49D can be blocked
by F(ab9)2 12A8. Neither F(ab9)2 12A8 nor control F(ab9)2
2C7 had any significant effect on the lysis of YB2/0.Db, Kb,
or Kk targets by any effector (panels B–D, F–H, and J–L).
RNK.mLy-49D Cells Are Activated by H-2d Con A Blasts.
We next extended our observations regarding the lysis of
transfected cells by examining the lysis of Con A blasts de-
rived from mice of various H-2 haplotypes. For these stud-
ies we tested RNK.mLy-49D effectors in cytotoxicity as-
says against Con A blasts prepared from MHC congenic
resistant strains of BALB/c and C57BL/10 mice.
As shown in Fig. 3, RNK.mLy-49D cells effectively
lysed Con A blasts prepared from BALB/c (H-2d; panel A)
and B10.D2 (H-2d; panel B) mice, but not Con A blasts
prepared from BALB.B10 (H-2b; panel C), C57BL/6 (H-
2b; panel D), BALB.K (H-2k; panel E), or B10.BR (H-2k;
panel F) mice. In experiments not shown, RNK.mLy-49D
effectors also lysed Con A blasts from DBA/2 (H-2d) mice
but not blasts from C3H (H-2k) or B10.S (H-2s) mice. Ly-
sis of all H-2d blasts by RNK.mLy-49D effectors was in-
hibited by anti–Ly-49D mAb 12A8, but not by isotype-
matched control mAb 2C7 (panels A and B).
These studies fully supported our experiments with
transfected tumor targets, identifying an H-2d–encoded
structure or structures as ligands for Ly-49D. Notably, Con
A blasts expressing alleles of H-2k failed to activate Ly-49D
transfectants. Thus, in constrast to the Ly-49A receptor,
Ly-49D does not recognize H-2Dk.
The a1/a2 Domains of H-2Dd Are Required for Recognition by
mLy-49D. We next examined the domains of H-2Dd that
are recognized by Ly-49D. To this end, we examined the
lysis by RNK.mLy-49D effectors of YB2/0 cells transfected
with genes in which exons for the a1, a2, and a3 domains of
H-2Dd and H-2Db were recombined to create chimeric class
I molecules. As shown in Fig. 4 C, the chimeric molecule
Dba1,2Dd, containing only the a3 domain of Dd, failed to acti-
vate cytotoxicity by RNK.mLy-49D cells, whereas the chi-
meric H-2 molecule Dda1,2Db, which contains the a1,2 do-
mains of Dd and the a3 domain of Db, activated cytotoxicity
by these cells (panel F). Augmentation of RNK.mLy-49D
lysis of Dda1,2Db was inhibited by F(ab9)2 anti–Ly-49D, but
not by control F(ab9)2 (panel F). As controls for the specific
effect of the mAb on the Ly-49D receptor, lysis of targets ex-
pressing Dba1,2Dd by either RNK-16 or RNK.mLy-49A
cells was unchanged by F(ab9)2 12A8 or control F(ab9)2 (pan-
els A and B). As we have previously shown, RNK.mLy-49A
effectors were unable to lyse YB2/0 cells expressing Dda1,2Db
(29). However, lysis of this target by RNK.mLy-49A could
be restored by the addition of blocking F(ab9)2 12A8 (panel
E). Thus, both Ly-49D and Ly-49A bind to the a1 and a2
domains, but not the a3 domain, of H-2Dd.
Previous studies have shown that the mLy-49A/H-2Dd
interaction can be blocked by one anti–H-2Dd antibody
(34-5-8S), which is specific for a conformationally depen-
dent epitope in the H-2Dd a1/a2 domains. Other mAbs to
H-2Dd do not interrupt its interaction with Ly-49A (32).
Figure 3. The Ly-49D receptor activates lysis of H-2d–expressing Con
A blasts. RNK.mLy-49D transfectants were tested as effector cells for lysis
of Con A blast targets prepared from mice that were congenic resistant at
the H-2 locus. Con A blasts were prepared from splenocytes isolated from
mice expressing either H-2d (BALB/c, B10.D2; panels A and B), H-2b
(BALB.B, C57BL/6; panels C and D), or H-2k (BALB.K, B10.BR; pan-
els E and F). Assays were performed after preincubation of effector cells
with media alone (h), anti–Ly-49D mAb (12A8) (r), or control mAb
(2C7) (s) before addition of targets.
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We, therefore, determined whether F(ab9)2 34-5-8S could
inhibit the Ly-49D/H-2Dd interaction as well. As shown
in Fig. 5, activation of RNK.mLy-49D effectors by YB2/
0.Dd was inhibited by F(ab9)2 34-5-8S (panel C), whereas
lysis of YB2/0.Dd by RNK.mLy-49A effectors was re-
stored in the presence of F(ab9)2 34-5-8S. RNK-16 lysis of
YB2/0.Dd was unaffected by F(ab9)2 34-5-8S.
These data show that the activating Ly-49D receptor
shares some aspects of ligand recognition with the inhibi-
tory Ly-49A receptor. Both receptors recognize the a1/a2
domains of H-2Dd, and F(ab9)2 anti–H-2Dd 34-5-8S can
block the interaction of H-2Dd with either Ly-49A or Ly-
49D. However, the ligand specificity of Ly-49D does not
completely mirror that of Ly-49A, as Ly-49D–mediated
cytotoxicity is not activated by H-2k blasts, which express
the Ly-49A ligand H-2Dk (33–35). These data suggest that
the structural features that restrict the allelic specificities of
Ly-49D and Ly-49A are similar, but not identical.
Discussion
Cytotoxicity by NK cells is generally inhibited by the
expression of class I MHC antigens on target cells. The
“missing self ” hypothesis proposes that loss of target cell
MHC class I may lead to the unopposed activation of natu-
ral killing and eventually to target cell lysis (5). However,
several previous lines of evidence suggest that rodent NK
cells may possess activating receptors in addition to inhibi-
tory receptors for MHC-encoded target structures. First,
irradiated C57BL/6 (H-2b) mice rapidly reject bone mar-
row from H-2Dd transgenic C57BL/6 mice, unless recipi-
ent mice are depleted of NK cells before transplantation
(19, 20). Thus, the transgenic expression of H-2Dd on
C57BL/6 blasts is associated with the selective acquisition
of susceptibility to lysis by mouse NK cells. Second, genetic
studies in rats have shown that NK cells are activated by
structures encoded within the MHC locus, and NK cells
from the PVG (RT1c) rat strain efficiently lyse blast targets
from LEW (RT1l) rats, but not from mutant LEW.LM1
(RT1lm1) rats, which have a homozygous 100-kb deletion
in the nonclassical RT1.Cl region (21). These data suggest
that the ability of NK cells to lyse allogeneic blast targets
may directly involve activating receptors for target MHC.
A gene controlling NK alloactivating responses in rats has
been linked to the Ly-49 gene family in NK alloresponder
PVG rats backcrossed to DA rats, which are selectively de-
Figure 4. The a1/a2 region of
H-2Dd is required to activate mLy-
49D. RNK-16 cells (A and D),
RNK.mLy-49A transfectants (B and
E), and RNK.mLy-49D transfec-
tants (C and F) were used as effectors
against YB2/0 cells expressing chi-
meric class I molecules Dba1,2Dd
(A–C) or Dda1,2Db (D–F) as target
cells in standard 4-h cytotoxicity
assays. Effector cells were preincu-
bated with media alone (h), anti–
Ly-49D (12A8) F(ab9)2 fragments
(r), or control (2C7) F(ab9)2 frag-
ments (s).
Figure 5. Activation of Ly-49D by H-2Dd
is inhibited by an antibody specific for the
a1/a2 domains of H-2Dd. Effector cells
RNK-16 (A), RNK.mLy-49A transfectants
(B), and RNK.mLy-49D transfectants (C)
were tested in a standard 4-h cytotoxicity
assay against YB2/0 targets expressing Dd
(YB2/0.Dd) in the presence of media alone
(h) or anti–H-2Dd F(ab9)2 fragments (34-
5-8S) (r).
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ficient in NK allorecognition. These studies implicate Ly-
49–like molecules in the activation of cytotoxicity by target
MHC antigens (22).
Mason et al. previously demonstrated that Ly-49D can
activate NK cell cytotoxicity, but the specific activation of
Ly-49D1 NK cells by target MHC class I antigens was not
demonstrated in vitro (14). Subsequent in vivo studies
revealed that depletion of Ly-49D1 cells from C57BL/6
mice prevented their ability to reject H-2Dd1 bone mar-
row grafts (23), consistent with the hypothesis that these
cells are functionally activated by MHC-encoded struc-
tures. We examined target-induced Ly-49D activation
using RNK.mLy-49D transfectants, which can activate
NK cell cytotoxicity through the Ly-49D receptor. In-
terestingly, when compared with wild-type RNK-16,
RNK. mLy-49D effectors demonstrated diminished lysis of
YAC-1 and YB2/0, as well as diminished antibody-depen-
dent cellular cytotoxicity and diminished redirected lysis
through the rat NKR-P1A receptor (data not shown).
This change was not associated with changes in expres-
sion of NKR-P1A on the RNK-16 transfectants (data not
shown). Because these changes in cytolytic specificity
were seen in three different RNK.mLy-49D clones, it
seems unlikely that they were unique to Ly-49D integra-
tion sites in stable transfectants, although this possibility
cannot be ruled out completely. It is also possible that the
overexpression of the Ly-49D activating receptor leads to
sequestration of signaling intermediates required for acti-
vation, which, in turn, leads to a decrease in lysis through
other activating receptors. However, we were easily able
to observe specific activation through Ly-49D, demon-
strating that the cytolytic capacity of RNK.mLy-49D cells
was intact.
Our in vitro studies demonstrate that Ly-49D is an acti-
vating NK cell receptor specific for H-2Dd. The acquisi-
tion of enhanced cytotoxicity against H-2Dd–transfected
YB2/0 targets was specifically blocked by F(ab9)2 anti–Ly-
49D or by F(ab9)2 anti–H-2Dd. Activation of NK cells by
Ly-49D was not unique to transfected targets, as Ly-49D
also stimulated lysis against blasts from H-2d mice, but not
against blasts from H-2b or H-2k mice. We considered the
possibility that these results might be obtained if Ly-49D
were not the activation receptor itself but instead, through
its interaction with H-2Dd, facilitated activation through a
separate activating receptor. However, it is unlikely that
adhesion alone between Ly-49D and H-2Dd accounts for
the observed activation of cytotoxicity. First, stimulation of
the Ly-49D receptor with antibody is known to induce ac-
tivation of cytotoxicity by NK cells, as shown here and by
others (14). Second, we have previously demonstrated that
adhesion between another Ly-49 receptor and H-2Dd is
not sufficient to activate NK cell lysis. Specifically, we have
previously demonstrated that interaction of an inactive Ly-
49A receptor with H-2Dd does not activate NK cell lysis
through other receptors on RNK-16 (25). The Ly-49A re-
ceptor normally binds to H-2Dd and thereby leads to inhi-
bition of NK cell lysis. Our previous studies showed inhi-
bition of lysis of H-2Dd expressing targets by RNK-16 cells
transfected with Ly-49A. We also studied a mutated Ly-
49A receptor, containing a point mutation in the cytoplas-
mic domain of the receptor which disrupts the ITIM mo-
tif required for inhibitory function. This mutated Ly-49A
receptor expressed on RNK-16 cells failed to inhibit or to
augment lysis of H-2Dd–expressing targets. This mutated
Ly-49A receptor is unaltered in the extracellular or trans-
membrane domains so its binding to H-2Dd is presumably
unaltered. Thus, engagement of H-2Dd by the mutant Ly-
49A receptor does not facilitate the activation of lytic path-
ways through other receptors on RNK-16.
It is of considerable interest whether the inhibitory Ly-
49A receptor and the activating Ly-49D receptor recognize
the same or distinct domains of the H-2Dd antigen. As with
Ly-49A, Ly-49D–dependent effects required the a1/a2 do-
mains of H-2Dd and could be blocked by an a1/a2-specific
F(ab9)2 anti–H-2Dd mAb (34-5-8S) (references 32–34, 36).
The extracellular domains of Ly-49A and Ly-49D may rec-
ognize similar regions of H-2Dd, but only Ly-49A recog-
nizes H-2Dk (33–35). Thus, Ly-49A and Ly-49D appear to
exhibit overlapping but distinct allelic specificities for mu-
rine class I MHC antigens. Studies by several groups have
indicated that Ly-49A does not discriminate between dif-
ferent peptides presented by H-2Dd (32, 37). The role of
antigenic peptides in the specificity of Ly-49D–H-2Dd in-
teraction remains to be examined.
It has been speculated that activating Ly-49–like recep-
tors may participate in the recognition of abnormal or vi-
rally-encoded MHC-like molecules by NK cells, although
this has not been proven (6, 38). However, the physiologic
significance of alloactivating NK receptors is unknown. Al-
though their effects may be partially masked by inhibitory
NK cell receptors, the identification of in vivo NK alloacti-
vating functions indicates that alloactivation is not com-
pletely abrogated by inhibitory MHC receptors in vivo
(19–22). A delicate balance between activating and inhibi-
tory alloreceptors may be influenced by different affinities
or structural requirements for ligand binding. Alternatively,
expression of opposing alloreceptors on different NK cell
subsets may permit NK alloresponses in vivo. Alloactivat-
ing NK cell receptors, in addition to allospecific T cell re-
ceptors, likely play a role in the physiologic rejection of
foreign cells (6, 7, 23, 39).
In conclusion, our experiments using gene transfer pro-
vide the first direct evidence that an activating receptor on
murine NK cells specifically directs cytotoxicity against a
classical class I MHC ligand. They also provide a model for
dissecting the molecular pathways involved in this interac-
tion. Other candidate alloactivating receptors on human NK
cells include the Ig-like short domain KIR (killer cell inhibi-
tory receptor) receptors, which may recognize alleles of
HLA-C (8, 15, 16), and the activating CD94/NKG2C re-
ceptor, which can bind to ligand HLA-E (11). Future studies
to define the distribution and activation requirements for
these receptors will help us to understand the physiologic
functions of alloactivating receptors in NK cell biology.
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